CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0059-000 |
|---|---|
| Brand Name | Cyramza |
| Generic Name | Ramucirumab |
| Strength | 10 mg/mL |
| Tumour Type | Gastrointestinal |
| Indication | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma |
| Funding Request | As a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma after prior chemotherapy |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | July 16, 2015 |
| Manufacturer | Eli Lilly Canada Inc. |
| Sponsor | Eli Lilly Canada Inc. |
| Submission Date | April 15, 2015 |
| Submission Deemed Complete | April 22, 2015 |
| Submission Type | Initial |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | April 29, 2015 |
| Check-point meeting | June 5, 2015 |
| pERC Meeting | August 20, 2015 |
| Initial Recommendation Issued | September 3, 2015 |
| Feedback Deadline ‡ | September 18, 2015 |
| pERC Reconsideration Meeting | October 15, 2015 |
| Final Recommendation Issued | October 29, 2015 |
| Notification to Implement Issued | November 13, 2015 |
| Therapeutic Area | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
